Mineralocorticoid receptor antagonist indication and underuse in high-risk post-myocardial infarction patients
Eur J Heart Fail
.
2024 Jan;26(1):140-141.
doi: 10.1002/ejhf.3098.
Epub 2023 Dec 20.
Authors
João Pedro Ferreira
#
1
2
,
Xavier Rossello
#
3
4
5
,
Faiez Zannad
2
Affiliations
1
Department of Surgery and Physiology, Cardiovascular R&D Centre - UnIC@RISE, Faculty of Medicine of the University of Porto, Porto, Portugal.
2
Inserm, Centre d'Investigation Clinique Plurithématique 1433, CHRU de Nancy, F-CRIN INI-CRCT, Université de Lorraine, Nancy, France.
3
Cardiology Department, Institut d'Investigació Sanitària Illes Balears (IDISBA), Hospital Universitari Son Espases, Palma, Spain.
4
Clinical Research Department, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
5
Faculty of Medicine, Universitat de les Illes Balears (UIB), Palma, Spain.
#
Contributed equally.
PMID:
38013392
DOI:
10.1002/ejhf.3098
No abstract available
Publication types
Editorial
MeSH terms
Heart Failure*
Humans
Mineralocorticoid Receptor Antagonists / therapeutic use
Myocardial Infarction* / drug therapy
Spironolactone
Substances
Mineralocorticoid Receptor Antagonists
Spironolactone